CaliPharms, Inc. / Fundamentals
Income statement
- Net revenue
€95.93K - Cost of goods sold
€122.00K - Gross profit
-€26.07K - SG&A expenses
€675.20K - R&D expenses
€0.00 - EBITDA
-€927.15K - D&A
-€225.88K - EBIT
-€701.27K - Interest expenses
€2.21M - EBT
-€5.45M - Tax expenses
€639.52K - Net income
-€5.45M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€4.80M - Changes in working capital
€48.76K - Operating cash flow
-€599.68K - Capex
€0.00 - Other investing cash flow
€0.00 - Net investing cash flow
-€31.91K - Total cash dividends paid
€0.00 - Issuance of common stock
€0.00 - Debt repayment
€638.06K - Other financing cash flow
€8.13K - Net financing cash flow
€646.20K - Foreign exchange effects
€0.00 - Net change in cash
€14.61K - Cash at end of period
€14.64K - Free cash flow
-€599.68K
Balance sheet
- Cash and cash equivalents
€14.64K - Cash and short-term investments
€14.64K - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€0.00 - Total current assets
€14.64K - Property, plant & equipment
€0.00 - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€0.00 - Total non-current assets
€0.00 - Total assets
€14.64K - Accounts payable
€1.50M - Short-term debt
€189.83K - Other current liabilities
€5.83M - Total current liabilities
€7.51M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€0.00 - Total liabilities
€7.51M - Common stock
€2.87K - Retained earnings
-€28.95M - Other equity
€0.00 - Total equity
-€7.50M - Total liabilities and shareholders' equity
€14.64K
Company information
- Market capitalization
€10.12K - Employees
0 - Enterprise Value
€11.86K
Company ratios
- Gross margin
-
-27.2% Much worse than peer group: 187.4% - EBITDA margin
-
-966.5% Much worse than peer group: 11,599.8% - EBIT margin
-
-731.0% Much better than peer group: -8,119.1% - EBT margin
-
-5,677.8% Much worse than peer group: 9,629.1% - Net margin
-
-5,677.8% Much worse than peer group: 9,509.9% - ROE
-
72.6% Better than peer group: 58.2% - ROA
-
-37,207.6% Much better than peer group: -777,847.7% - Asset turnover
-
655.3% Much worse than peer group: 1,366.2% - FCF margin
-
-625.1% Much worse than peer group: 1,879.9% - FCF yield
-5,928.5% - Efficiency ratio
1,066.5% - Net sales per employee
-
€0.00 - Net income per employee
-
€0.00